ArticleLupus science & medicine2026
Belimumab as a possible treatment for SLE-associated pulmonary arterial hypertension: the experience from a single centre.
Article in Lupus science & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore clinical outcomes associated with belimumab use in patients with SLE-associated pulmonary arterial hypertension (SLE-PAH).
methodsWe performed an ambispective cohort study of 10 patients with SLE-PAH treated with intravenous belimumab (10 mg/kg) from January 2022 to January 2025 and compared them with 30 matched SLE-PAH controls receiving conventional immunosuppression without biologics. Patients were followed for 12 months by the same medical team. Clinical, laboratory, echocardiographic parameters, SLE Disease Activity Index 2000 and PAH risk stratification were compared between groups.
resultsAll patients were matched according to baseline age, sex, WHO functional class (WHO-FC), PAH treatment strategy and background SLE therapy. All enrolled patients received either dual or triple combination targeted therapy for PAH. In the SLE-PAH group treated with belimumab, rapid and sustained improvements were observed in multiple parameters, including N-terminal pro-B-type natriuretic peptide, WHO-FC, 6-minute walking distance, soluble suppression of tumorigenicity 2 levels, the ratio of tricuspid annular plane systolic excursion to pulmonary artery systolic pressure (TAPSE/PASP) and right ventricular end-diastolic basal dimension (RVDd). Compared with the matched control group, belimumab-treated patients showed greater improvement in TAPSE/PASP and RVDd at the 12-month follow-up, with statistically significant differences between groups. Additionally, at the 12-month follow-up, all patients in the belimumab group were stratified into the low-risk category, whereas one patient remained in the intermediate-low risk and four patients were categorised as intermediate-high risk in the matched group.
conclusionBelimumab combined with standard PAH-targeted therapy was associated with improvements in right ventricular structure and function in patients with SLE-PAH compared with conventional immunosuppression. Further large-scale, prospective investigations are warranted to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.